Fevipiprant | B1588

Fevipiprant is a prostaglandin D2 (PGD2) receptor antagonist with a Kd value of 1.14 nM for CRTH2/DP2. It has been shown to inhibit PGD2-stimulated human eosinophil shape change in whole blood assays (IC₅₀ = 0.44 nM) and to inhibit PGD2-induced cytokine release in human Th2 cells (IC₅₀s = 2.56 and 1.4 nM for IL-5 and IL-13, respectively). This compound has undergone testing in a phase II clinical study in uncontrolled allergic asthma.

Fevipiprant is a prostaglandin D2 (PGD2) receptor antagonist with a Kd value of 1.14 nM for CRTH2/DP2. It has been shown to inhibit PGD2-stimulated human eosinophil shape change in whole blood assays (IC₅₀ = 0.44 nM) and to inhibit PGD2-induced cytokine release in human Th2 cells (IC₅₀s = 2.56 and 1.4 nM for IL-5 and IL-13, respectively). This compound has undergone testing in a phase II clinical study in uncontrolled allergic asthma.

B1588 | Fevipiprant DataSheet

Alternate Name/Synonyms: 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; NVP-QAW039; QAW039

Appearance: White to of-white solid

Formulation: N/A

CAS Number: 872365-14-5

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: N/A

Molecular Formula: C₁₉H₁₇F₃N₂O₄S

Molecular Weight: 426.41

Cell-Permeable?: yes

Purity: ≥98% by HPLC

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A prostaglandin D2 (PGD2) receptor antagonist

MDL Number: N/A

PubChem CID: 23582412

SMILES: CC1=C(C2=C(N1CC3=C(C=C(C=C3)S(=O)(=O)C)C(F)(F)F)N=CC=C2)CC(=O)O

InChi: InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)

InChi Key: GFPPXZDRVCSVNR-UHFFFAOYSA-N